Synthesis and Evaluation of a 3, 4‐dihydro‐2H ‐benzoxazine Derivative as a Potent CDK9 Inhibitor for Anticancer Therapy

[1]  Concha Sánchez-Martínez,et al.  Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019). , 2019, Bioorganic & medicinal chemistry letters.

[2]  C. Ricciardelli,et al.  Targeting CDK9 for treatment of colorectal cancer , 2019, Molecular Oncology.

[3]  H. Briem,et al.  Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer , 2017, ChemMedChem.

[4]  A. Giordano,et al.  Overview of CDK9 as a target in cancer research , 2016, Cell cycle.

[5]  Harald Schwalbe,et al.  A Nucleus-Imaging Probe That Selectively Stabilizes a Minor Conformation of c-MYC G-quadruplex and Down-regulates c-MYC Transcription in Human Cancer Cells , 2015, Scientific Reports.

[6]  R. Gaynor,et al.  A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models , 2014, Molecular Cancer Therapeutics.

[7]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[8]  P. Dent,et al.  Characterization of Cdk9(55) and differential regulation of two Cdk9 isoforms. , 2005, Gene.

[9]  Dawn R. Chin,et al.  Cyclin-dependent Kinase 9 Is Required for Tumor Necrosis Factor-α-stimulated Matrix Metalloproteinase-9 Expression in Human Lung Adenocarcinoma Cells* , 2005, Journal of Biological Chemistry.

[10]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.